We met with Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori) at ESMO 2019 to discuss the 3-year follow-up results from the phase III KEYNOTE-045 trial: Pembrolizumab Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (NCT02256436).
1. What are the limitations of the current standard of care for the second-line treatment of patients with recurrent urothelial cancer? (0:05)
2. Could you tell us a little about the aims and design of the KEYNOTE-045 study? (3:44)
3. What is the role of programmed death-ligand 1 (PD-L1) expression in predicting response? (6:02)
4. What future studies of pembrolizumab in urothelial cancer are planned? (7:36)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Andrea Necchi has received honoraria from Roche, Merck, AstraZeneca, Janssen, and Foundation Medicine; has served as a consultant/advisor for Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol-Myers Squibb, and Rainier Therapeutics; has received institutional research funding from Merck Sharp & Dohme and AstraZeneca; has received travel expenses from Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, and Rainier Therapeutics; and has an immediate family member who has other relationships with Bayer.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Genitourinary Cancers
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!